Sex Disparities in Diabetes Process of Care Measures and Self-Care in High-Risk Patients
Table 4
Logistic regression models of diabetes process measures for women compared to men amongst subjects with diabetic complications.
Unadjusted OR (95% CI)
Adjusted OR (95% CI)*
Hemoglobin A1c testing (12 months)
0.90 (0.65–1.23)
0.51
0.94 (0.66–1.34)
0.75
LDL testing (12 months)
0.67 (0.58–0.78)
<0.001
0.65 (0.54–0.77)
<0.001
Microalbuminuria testing (24 months)
1.10 (0.95–1.28)
0.21
1.06 (0.88–1.28)
0.51
Hemoglobin A1c < 7%
1.12 (0.95–1.31)
0.17
1.21 (1.01–1.44)
0.04
LDL < 130 mg/dL
0.65 (0.54–0.79)
<0.001
0.63 (0.51–0.78)
<0.001
Statin
0.64 (0.55–0.74)
<0.001
0.67 (0.56–0.79)
<0.001
Statin if LDL >130 mg/dL
0.71 (0.50–1.03)
0.07
0.64 (0.42–0.97)
0.04
ACE inhibitor
0.87 (0.75–1.01)
0.07
0.87 (0.73–1.03)
0.10
ACE inhibitor if microalbuminuria
1.08 (0.84–1.40)
0.54
1.10 (0.83–1.47)
0.51
Adjusted for age, race, marital status, education, smoking, body mass index, hemoglobin A1c (except models for hemoglobin A1c testing and hemoglobin A1c <7%), and history of hypertension. LDL: low-density lipoprotein; ACE: angiotensin converting enzyme.
